Endevica Bio

Endevica Bio has dosed the first patient in a Phase 2 trial evaluating TCMCB07 (B07) to prevent weight loss and cachexia in stage 4 metastatic colorectal cancer patients undergoing chemotherapy.

Endevica Bio has received FDA authorization to begin a Phase 2 clinical trial of TCMCB07 (B07), a peptide designed to prevent weight loss in stage 4 metastatic colorectal cancer patients undergoing chemotherapy.

Endevica Bio has established a new spin-off company, Abisati, dedicated to developing 710GO, a melanocortin-targeting peptide that demonstrated 7.5% weight loss in preclinical monkey studies.

Cancer cachexia, a devastating wasting syndrome affecting up to 40% of cancer patients, is gaining recognition as a critical therapeutic target beyond traditional tumor-focused treatments.